Dallas-based Nanoscope Therapeutics has appointed Khandan Baradaran, PhD, as senior vice president of regulatory and quality, bringing with her nearly two decades of extensive experience in manufacturing and regulatory review of gene therapy products, including regulatory and chemistry, manufacturing, and controls experience.
Nanoscope is a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations.
“Khandan’s experience leading quality and compliance for rare genetic disease biopharmaceutical companies will be valuable as we continue to advance our versatile MCO platform, including MCO-010, which is driving our expanding pipeline of programs,” Co-Founder and CEO Sulagna Bhattacharya said in a statement. “This appointment supports the continued advancement of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and further highlights our continued growth as a company.”
“I’m honored to join the highly motivated team at Nanoscope in the development of its novel approach to treating retinal degenerative diseases,” Baradaran said. “Following the impressive durable efficacy and safety results from the randomized control trial in retinitis pigmentosa, I eagerly anticipate contributing to Nanoscope’s advancement as we navigate forthcoming regulatory milestones and prepare for commercial readiness.”
Most recently, Baradaran was vice president of regulatory CMC at Ultragenyx Pharmaceutical, a biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases.
Before that, Baradaran was vice president and head of quality at Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Prior to that, she held CMC and regulatory positions at Biogen, Novartis, and Dyax.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.
R E A D N E X T
-
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
-
Splendorio's more than 30 years of experience have been marked by extensive executive leadership in the ophthalmic industry, and he will support Nanoscope in reaching its strategic vision, the company said.
-
Najam Sharif, Ph.D., DSc, has been appointed as vice president of global research and development by Dallas-based Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases. Sharif is a veteran in drug/device discovery and development, the company said. "We are delighted to welcome Naj to the Nanoscope team," Sulagna Bhattacharya, co-founder and CEO of Nanoscope, said in a statement. "His extensive experience in ophthalmology and pharmaceutical drug discovery and development is a natural fit for our organization, and we look forward to drawing on his clinical and regulatory expertise in particular at this pivotal time…
-
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
-
Newly appointed business advisory board member Daniel Feller is "a pillar of the rare genetic disease community in Australia," according to Nacuity co-founder and CEO Halden Conner.
